Current Complexities and Controversies in Pharmacovigilance, Signal, and Risk Management

OVERVIEW:
This global three-day meeting will provide new insights into the current issues and associated challenges impacting drug safety, focusing primarily on drug products and biologics, throughout all phases of development and marketed use. Top pharmaceutical, biotechnology, and regulatory thought leaders convene each January to discuss new and updated legislation in various ICH regions, current regulatory framework for pharmacovigilance in global regions, operational challenges of implementing global Benefit-risk analyses and risk management plans, the impact of social media, and the role of epidemiology in safety analysis.

LEARNING OBJECTIVES:
At the conclusion of this meeting, participants should be able to:
• Describe the current global regulatory framework for pharmacovigilance and the move toward harmonization
• Describe operational challenges of implementing global Benefit-risk analyses and risk management plans
• Discuss how information technologies and social media are impacting pharmacovigilance
• Examine the role of epidemiology in safety analysis

TUTORIAL TOPICS:
• Pharmacovigilance and Risk Management Planning
• Introduction to Pharmacoepidemiology and Applications in Premarketing and Postmarketing Surveillance, Risk Management, And Value Demonstration
• Pharmacovigilance System Master File
• ICH E2C (R2): The Quantum Leap from PSURs to Benefit-Risk Evaluation (PBRERs)

Register at diahome.org/Safety2014
CONTINUING EDUCATION

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and the Drug Information Association. PIM is accredited by the ACCME to provide continuing medical education for physicians.

DIA is required by the Accreditation Council for Pharmacy Education (ACPE) to report pharmacy-requested CEUs through the CPE Monitor system. All ACPE-certified activity credit requests need to be submitted through DIA’s My Transcript within 45-days post activity. Pharmacists will need to provide their National Association of Boards of Pharmacy (NABP) e-Profile ID and date of birth (MMDD) to ensure the data is submitted to the ACPE and NABP properly. If you need to obtain your NABP e-Profile, please visit www.cpemonitor.net.

As an IACET Authorized Provider, Drug Information Association offers CEUs for its programs that qualify under the ANSI/IACET Standard. Drug Information Association is authorized by IACET to offer up to 2.3 CEUs for the program. Participants must attend the entire program and tutorial(s), in order to be able to receive an IACET statement of credit. No partial credit will be awarded.

If you would like to receive a statement of credit, you must attend the program and tutorial(s) if applicable, sign-in at the DIA registration desk each day of the program and complete the online credit request process through My Transcript. To access My Transcript, please go to diahome.org select “Login to My DIA” and you will be prompted for your user ID and password. Select “My Transcript” (left side bar) and “Credit Request” to process your credit request. Participants will be able to download a statement of credit upon successful submission of the credit request. My Transcript will be available for credit requests on Wednesday, January 29, 2014.

The Postgraduate Institute for Medicine (PIM) and DIA require instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM and DIA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

CONTINUING EDUCATION CREDIT ALLOCATION

Tutorials:
- Tutorial #1: Pharmacovigilance and Risk Management: Planning: Pharmacy: 3.25 contact hours or .325 CEUs, 0286-0000-14-019-L04-P; Nursing: 3.25 contact hours; IACET: .3 CEUs
- Tutorial #2: Introduction to Pharmacoepidemiology and Applications in Premarketing and Postmarketing Surveillance, Risk Management and Value Demonstration: Nursing: 3.25 contact hours; IACET: .3 CEUs
- Tutorial #3: ICH E2C (R2): The Quantum Leap from PSURs to Benefit-Risk Evaluation (PBRRs): Nursing: 3.25 contact hours; IACET: .3 CEUs
- Tutorial #4: Pharmacovigilance System Master File: Nursing: 3.25 contact hours; IACET: .3 CEUs

Meeting:
- COREXCEL: 16.5 AMA PRA Category 1 Credit(s)TM
- Nursing: 16.5 contact hours
- IACET: 1.7 CEUs
- Pharmacy:
  - Session 1 – Keynote Presentation: Digital Disease Detection: 1.25 contact hours or .125 CEUs, 0286-0000-14-020-L04-P
  - Session 7 – Benefit-Risk and Risk Management: 1.5 contact hours or .15 CEUs, 0286-0000-14-021-L04-P
  - Session 8 – Patient Perspective: 1.5 contact hour or .15 CEUs, 0286-0000-14-022-L04-P
  - Session 9, Part II – Real World Evidence: Safety Applications: 1.5 contact hours or .15 CEUs, 0286-0000-14-023-L04-P
  - Session 10 – Social Media: 1.5 contact hours or .15 CEUs, 0286-0000-14-024-L04-P

It is Drug Information Association policy that anyone in a position to control the content of a continuing education activity must disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and/or the educational activity, and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. Faculty disclosures will be included in the course materials.

Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organization they represent, or that of the Drug Information Association. Speakers, agenda, and CE information are subject to change without notice. Recording of any DIA educational material in any type of media, is prohibited without prior written consent from DIA.

View DIA’s Grievance Policy at diahome.org/CE

DIA’S CERTIFICATE PROGRAM

This program is part of DIA’s Certificate Program and is awarded the following:
- Clinical Research Certificate Program: 12 Elective Units
- Clinical Safety and Pharmacovigilance Certificate Program: 4 Elective Units
- Regulatory Affairs Certificate Program: 12 Elective Units

For more information go to diahome.org/certificateprograms

TO ACCESS PRESENTATIONS:
- Visit diahome.org
- Login to My DIA
- Enter your User ID and Password
- View ‘My Presentation Downloads’

Please Note: DIA User ID and Password are needed to access presentations. If you have forgotten your DIA User ID and Password, or this is your first time logging into the DIA website, please use our Login Reminder.
### AM TUTORIALS

#### Tutorial #1 – Pharmacovigilance and Risk Management Planning

**TUTORIAL INSTRUCTOR**
William W. Gregory, PhD  
Senior Director  
Safety and Risk Management  
Pfizer Inc.

This tutorial will focus on the practical aspects of managing biopharmaceutical product risks in the context of a product’s benefits.

**LEARNING OBJECTIVES:**
- Discuss similarities and differences in risk management planning in the three ICH regions
- Describe the differences between important identified risks and important potential risks
- Outline the basic structure and contents of an EU Risk Management Plan (in the context of a Risk Management System) and a Risk Evaluation and Mitigation Strategy (REMS)
- Discuss primary tools for managing product risks, how the effectiveness of a selected tool is assessed, and triggers for modification or removal of a given intervention

#### Tutorial #2 – Introduction to Pharmacoepidemiology and Applications in Premarketing and Postmarketing Surveillance, Risk Management, and Value Demonstration

**TUTORIAL INSTRUCTORS**
Annette Stemhagen, DrPH, FISPE  
Senior Vice President  
Safety, Epidemiology, Registries and Risk Management  
United BioSource Corporation  
Robert Sharrar, MD  
Executive Director  
Safety, Epidemiology, Registries and Risk Management  
United BioSource Corporation

This tutorial will provide an overview of basic epidemiology methods and study designs as they are applied in the pharmaceutical and biotechnology industries. Topics will include design and conduct of retrospective and prospective epidemiologic studies such as case-control studies and cohort studies, and the application of these designs for premarketing and postmarketing surveillance, risk management (risk assessment and risk mitigation), and demonstration of product value.

**LEARNING OBJECTIVES:**
- Define basic epidemiologic principles
- Distinguish case-control and cohort study designs
- Identify applications for epidemiology in pre- and postmarketing pharmaceutical product safety surveillance and risk management
- Identify applications for use of epidemiologic studies in demonstrating product value

### PM TUTORIALS

#### Tutorial #3 – ICH E2C (R2): The Quantum Leap from PSURs to Benefit-Risk Evaluation (PBRERs)

**TUTORIAL INSTRUCTORS**
Valerie E. Simmons, MD, FFPM  
EU Qualified Person for Pharmacovigilance  
Global Patient Safety  
Eli Lilly and Company Limited  
United Kingdom  
Ayman Ayoub, MD  
Disease Area Head  
Safety Surveillance and Risk Management  
Pfizer LTD Central Research  
United Kingdom  
Alison Turney, PharmD  
Consultant  
Surveillance Process Owner  
Eli Lilly and Company

The new ICH E2C (E2C) guideline on Periodic Benefit-Risk Evaluation Reports (PBRERs) reached Step 4 in November 2012 and has already implemented in the EU under the new Pharmacovigilance legislation. Also accepted in the US, Japan, and other countries, the PBRER may replace existing requirements for postmarketing periodic reporting. This new report represents a significant change from the previous PSUR format and a quantum leap forward towards a document incorporating many new concepts including an integrated evaluation of both benefits and risks of a medicinal product.

**LEARNING OBJECTIVES:**
- Discuss the main principles defined in the ICH E2C (R2) guideline
- Describe the structure and content of the new PBRER
- Explain the regulatory authority expectations of the PBRER
- Recognize some of the key implementation challenges and how they may be addressed
- Discuss the practical aspects in the preparation of the PBRER
Tutorial #4 - Pharmacovigilance System Master File (PSMF)

TUTORIAL INSTRUCTOR

Noha Kassem, PhD
Senior Director
Quality in Global Patient Safety
Eli Lilly and Company
United Kingdom

As part of the new EU Pharmacovigilance Legislation (Regulation EU 1235/2010 and Directive 2010/84/EU) marketing-authorization holders are required to maintain a Pharmacovigilance System Master File (PSMF). The PSMF must be in place at the time of initial marketing authorization application, license renewal and available for inspections. The PSMF replaced the Detailed Description of the Pharmacovigilance System (DDPS). This tutorial will cover the requirements in the PSMF, the creation and maintenance as well as sharing a real experience focusing on some of challenges and how they can be addressed.

LEARNING OBJECTIVES:
At the conclusion of this tutorial, participants should be able to:
• Discuss how to prepare a PSMF to meet the requirements
• Describe how to maintain a PSMF so that it can be available within seven days from request
• Examine challenges and possible scenarios of how to address preparation and maintenance

MONDAY, JANUARY 13

7:30-8:30AM CONTINENTAL BREAKFAST AND ATTENDEE REGISTRATION

8:30-8:45AM WELCOME AND OPENING REMARKS

Program Co-chairs

JP Clement, MD
Vice President
Drug Safety and Pharmacovigilance
Onyx Pharmaceuticals, Inc.

William W. Gregory
Senior Director
Safety and Risk Management
Pfizer Inc.

8:45-10:00AM SESSION 1

Keynote Presentation

SESSION CO-chairs

JP Clement, MD
Vice President
Drug Safety and Pharmacovigilance
Onyx Pharmaceuticals, Inc.

Digital Disease Detection

John Brownstein, PhD
Manager and Associate Professor
Boston Children’s Hospital and Harvard Medical School

10:00-10:30AM REFRESHMENT BREAK

10:30AM-12:00PM SESSION 2

FDA Updates

SESSION CHAIR

Gerald J. Dal Pan
Director
Office of Surveillance and Epidemiology
CDER, FDA

Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data

Judy Staffa, MD, PhD
Director
OSE Division of Epidemiology
CDER, FDA

Regulatory Updates from the FDA

Gerald J. Dal Pan
Director
Office of Surveillance and Epidemiology
CDER, FDA

12:00-1:30PM LUNCH
1:30-3:00pm  SESSION 3

Drug Safety in China – The Importance of What’s Happening
SESSION CHAIR
Stewart Geary, MD
Vice President, Deputy Director
Eisai Co., Ltd., Japan

Pharmacovigilance in China: The Current Landscape
Vera Liang
Global Safety Risk Lead and Director
Safety Surveillance and Risk Management
Pfizer R&D Co., Ltd., China

CRO Perspective
Deirdre McCarthy, MSc
Director
Integrated Post-marketing and QPPV Services
Customer Safety Services
Quintiles

Industry Perspective
William W. Gregory, PhD
Senior Director
Worldwide Safety and Regulatory
Pfizer, Inc.

3:00-3:30pm  REFRESHMENT BREAK

3:30-5:00pm  SESSION 4

Emerging Markets
SESSION CHAIR
Paula Taborelli
Regional Director Pharmacovigilance (EU & LA)
Global Pharmacovigilance & Epidemiology
Bristol-Myers Squibb

Japanese Perspective
Yoshinori Takeuchi, DVM, PhD, MPH
Pharmacoepidemiologist
Surveillance and Analysis Division, Office of Safety I
Pharmaceuticals and Medical Devices Agency (PMDA)

Latin America Perspective
Marisa Fernandes, BSN, RN
Manager
Drug Safety Center, Latin America
PRA International

India Perspective
Moin Don
Executive Director and Founder
PVCON Pharmacovigilance Consulting Services

5:00-6:00pm  NETWORKING RECEPTION

TUESDAY, JANUARY 14

7:30-8:30am  CONTINENTAL BREAKFAST AND ATTENDEE REGISTRATION

8:30-10:00am  SESSION 5

EU Regulations – Regulatory Overview
SESSION CO-CHAIRS
Vicki Edwards
Qualified Person for Pharmacovigilance and Head of Affiliate Vigilance Excellence
Abbvie Ltd.

Almath Spooner
Lead, Pharmacovigilance and Risk Management
IMB and Vice Chair, PRAC
Irish Medicines Board

Regulatory Overview
Mick Foy
Group Manager
Vigilance Intelligence and Research Group
MHRA

PRAC Perspective
Almath Spooner
Lead
Pharmacovigilance and Risk Management
IMB and Vice Chair, PRAC
Irish Medicines Board

Industry Perspective
Michael Richardson
International Head GPV&E and EU Qualified Person for Pharmacovigilance
Bristol-Myers Squibb

Panel Discussion
**SESSION 6**

**Harmonization**

**Session Chair**

Valerie E. Simmons, MD, FFPM  
EU Qualified Person for Pharmacovigilance  
Global Patient Safety  
Eli Lilly & Company Ltd.  
United Kingdom

**US Perspective**

Justina Molzon, JD, MPharm  
Associate Center Director for International Programs  
CDER, FDA

**Asian Perspective**

Stewart Geary, MD  
Vice President, Deputy Director  
Eisai Co., Ltd.  
Japan

**European Perspective**

Moira Daniels, MBA  
Vice President, Head Global Patient Safety Services, PACE  
PAREXEL International  
United Kingdom

**Legal Perspective**

Richard F. Kingham, Esq.  
Partner  
Covington & Burling

**SESSION 7**

**Benefit-Risk and Risk Management**

**Session Co-Chairs**

William W. Gregory, PhD  
Senior Director  
Safety and Risk Management  
Pfizer, Inc.

Michael Richardson  
International Head GPV&E and  
EU Qualified Person for Pharmacovigilance  
Bristol-Myers Squibb

**Benefit-Risk in Relation to Risk Management**

Susan Welsh  
Vice President  
Medical Safety  
Bristol-Myers Squibb

**Benefit-Risk Work Streams: Quantitative vs. Qualitative**

Rebecca A. Noel  
Senior Research Scientist  
Global Patient Safety  
Eli Lilly and Company

**Benefit-Risk from a Regulator’s Perspective**

Sara Eggers  
Operations Research Analyst  
Office of Program and Strategic Analysis  
CDER, FDA

**SESSION 8**

**Patient Perspective**

**Session Chair**

Peg Fletcher, MD, PhD  
President  
MedAssessment Inc.

**Speakers**

Eric Gascho  
Director, Government Affairs  
National Health Council

Diane D. Edquist Dorman  
Vice President, Public Policy  
National Organization For Rare Disorders (NORD)

5:00PM  
**END OF DAY 2**
WEDNESDAY, JANUARY 15

7:30-8:30AM  CONTINENTAL BREAKFAST AND ATTENDEE REGISTRATION

8:30-10:00AM  SESSION 9 – PART I

Real World Evidence: The Building Blocks

SESSION CHAIR

Mariette Boerstoel-Streefland, MD, MBA, MS(epi)
Chief Safety Officer, Vice President
Global Drug Safety
Forest Research Institute, a Subsidiary of Forest Laboratories Inc.

PROTECT

Robert Reynolds
Vice President, Global Head, Epidemiology
Pfizer Inc

Sentinel Updates

Katrina Mott, MHS
ORISE Fellow
CDER Sentinel Team
CDER, FDA

Partnerships Between Pharma and Database Owners

Andres Gomez
Head
Epidemiology, Signal Detection and Data Management
Bristol Myers Squibb

10:00-10:30AM  REFRESHMENT BREAK

10:30-12:00PM  SESSION 9 – PART II

Real World Evidence: Safety Applications

SESSION CHAIR

Stephen Knowles, MD, MRCP
Senior Director, Global Patient Safety
Eli Lilly and Company

Current Use of Real World Evidence of Signal Assessment

John D. Seeger, PharmD, DrPh
Assistant Professor
Harvard Medical School/Brigham & Women’s Hospital

Future of Large Databases in Data Mining

Andrew Bate
Senior Director, Analytics Team Lead
Epidemiologist, Worldwide Safety Strategy
Pfizer Inc

Assessing the Effectiveness of Risk Minimization Programs: Future Needs and Opportunities for Using Real World Evidence

Gary H. Slatko, MD
Director
Office of Medication Error Prevention and Risk Management, OSE
CDER, FDA

12:00-1:30PM  LUNCH

1:30-3:00PM  SESSION 10

Social Media

SESSION CO-CHAIRS

Elizabeth E. Garrard, PharmD
Senior Director
Safety Risk Management
United Therapeutics Corporation

Linda J. Scarazzini, MD
Vice President
Medical Safety Evaluation
AbbVie

FDA Perspective

Henry “Skip” Francis, MD
Director for Data Mining and Informatics Evaluation and Research
Office of Translational Sciences
CDER, FDA

Upstream Activities

Andrew R. Rut, MD
CEO
My Meds & Me

Safety & Social Media

Nabarun Dasgupta, MPH, PhD
Professor, University of North Carolina at Chapel Hill
Scientist, Epidemico

3:00PM  MEETING ADJOURNS